医学
一致性
新辅助治疗
危险系数
接收机工作特性
置信区间
分级（工程）
癌症
肿瘤科
放射科
内科学
乳腺癌
土木工程
工程类
作者
Sanja Đačić,William D. Travis,Jennifer M. Giltnane,Filip Kos,John H. Abel,Stephanie Hilz,Junya Fujimoto,Lynette M. Sholl,J. Ritter,Farah Khalil,Yi Liu,Amaro Taylor‐Weiner,Murray B. Resnick,Hui Yu,Fred R. Hirsch,Paul A. Bunn,David P. Carbone,Valerie W. Rusch,David J. Kwiatkowski,Bruce E. Johnson
标识
DOI：10.1016/j.jtho.2023.12.010
摘要
Pathologic response (PathR) by histopathologic assessment of resected specimens may be an early clinical end point associated with long-term outcomes with neoadjuvant therapy. Digital pathology may improve the efficiency and precision of PathR assessment. LCMC3 (NCT02927301) evaluated neoadjuvant atezolizumab in patients with resectable NSCLC and reported a 20% major PathR rate.
科研通智能强力驱动
Strongly Powered by AbleSci AI
cdercder
bc
昏睡的蟠桃
淡然的熊猫
back you up
lin
平常的毛豆
HEIKU
SYLH
ZhouYW
iNk
冰魂
科研小民工
Ankher
余味
孤独尔白
Auston_zhong
Leo
爱静静
Mercury
皖公网安备34019202002308
